We’d like to see your publications using OTB samples! Please email us at tumourbank@oicr.on.ca.

1) Fazzari J, Sidhu J, Motkur S, et al.

Applying Serum Cytokine Levels to Predict Pain Severity in Cancer Patients

J Pain Res. 2020;13:313-321. https://doi.org/10.2147/JPR.S227175

2) Rubanova Y, Shi R, Harrigan C, et al.

Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig

Nature Communications volume 11, Article number: 731 (2020). https://doi.org/10.1038/s41467-020-14352-7

3) Bhandari V, Li C, Bristow R.G, et al.

Divergent mutational processes distinguish hypoxic and normoxic tumours

Nature Communications volume 11, Article number: 737 (2020) . https://doi.org/10.1038/s41467-019-14052-x

4) Cmero M, Yuan K, Soon Ong C, et al.

Inferring structural variant cancer cell fraction

Nature Communications volume 11, Article number: 730 (2020) . https://doi.org/10.1038/s41467-020-14351-8

5) Shuai S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger S, et al.

Combined burden and functional impact tests for cancer driver discovery using DriverPower

Nature Communications volume 11, Article number: 734 (2020). https://doi.org/10.1038/s41467-019-13929-1

6) Sieverling L, Hong C, Koser S.D, et al.

Genomic footprints of activated telomere maintenance mechanisms in cancer

Nature Communications volume 11, Article number: 733 (2020). https://doi.org/10.1038/s41467-019-13824-9

7) Zhang Y, Chen F, Fonseca N.A, et al.

High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations

Nature Communications volume 11, Article number: 736 (2020) . https://doi.org/10.1038/s41467-019-13885-w

8) Jiao W, Atwal G, Polak P, et al.

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Nature Communications volume 11, Article number: 728 (2020). https://doi.org/10.1038/s41467-019-13825-8

9) Reyna M.A, Haan D, Paczkowska M, et al.

Pathway and network analysis of more than 2500 whole cancer genomes

10) Paczkowska M, Barenboim J, Sintupisut N, et al.

Integrative pathway enrichment analysis of multivariate omics data

Nature Communications volume 11, Article number: 735 (2020). https://doi.org/10.1038/s41467-019-13983-9

11) Carlevaro-Fita J, Lanzós A.

Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

Communications Biology volume 3, Article number: 56 (2020). https://doi.org/10.1038/s42003-019-0741-7

12) Yakneen S, Waszak S.M, PCAWG Technical Working Group, Gertz M, et al.

Butler enables rapid cloud-based analysis of thousands of human genomes

Nature Biotechnology volume 38, pages288–292 (2020). https://doi.org/10.1038/s41587-019-0360-3

13) Cortés-Ciriano I, Lee J JK, Xi R, et al.

Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing

Nature Genetics volume 52, pages331–341 (2020). https://doi.org/10.1038/s41588-019-0576-7

14) Zapatka M, Borozan I, Brewer D.S, et al.

The landscape of viral associations in human cancers

Nature Genetics volume 52, pages320–330 (2020). https://doi.org/10.1038/s41588-019-0558-9

15) Rodriguez-Martin B, Alvarez E.G, Baez-Ortega A, et al.

Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition

Nature Genetics volume 52, pages306–319 (2020). https://doi.org/10.1038/s41588-019-0562-0

16) Akdemir K.C, Le V.T, Chandran S, et al.

Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer

Nature Genetics volume 52, pages294–305 (2020). https://doi.org/10.1038/s41588-019-0564-y

17) Yuan Y, Ju Y.S, Kim Y, et al.

Comprehensive molecular characterization of mitochondrial genomes in human cancers

Nature Genetics volume 52, pages342–352 (2020). https://doi.org/10.1038/s41588-019-0557-x

18) Rheinbay E, Ju Y.S, Kim Y, et al.

Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

Nature volume 578, pages102–111 (2020). https://doi.org/10.1038/s41586-020-1965-x

19) PCAWG Transcriptome Core Group.

Genomic basis for RNA alterations in cancer

Nature volume 578, pages129–136 (2020). https://doi.org/10.1038/s41586-020-1970-0

20) Gerstung M, Jolly C, Leshchiner I, et al.

The evolutionary history of 2,658 cancers

Nature volume 578, pages122–128 (2020). https://doi.org/10.1038/s41586-019-1907-7

21) Alexandrov L.B, Kim J, Haradhvala N.J, et al.

The repertoire of mutational signatures in human cancer

Nature volume 578, pages94–101 (2020). https://doi.org/10.1038/s41586-020-1943-3

22) Li Y, Roberts N.D, Wala J.A, et al.

Patterns of somatic structural variation in human cancer genomes

Nature volume 578, pages112–121 (2020). https://doi.org/10.1038/s41586-019-1913-9

23) The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium.

Pan-cancer analysis of whole genomes

Nature volume 578, pages82–93 (2020). https://doi.org/10.1038/s41586-020-1969-6

24) Sindhwani S, Muhammad A, Ngai J, et al.

The entry of nanoparticles into solid tumours

Nature Materials volume 19, pages566–575 (2020). https://doi.org/10.1038/s41563-019-0566-2

25) Snider H, Villavarajan B, Peng Y, et al.

Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer

Clinical Epigenetics volume 11, Article number: 155 (2019). https://doi.org/10.1186/s13148-019-0750-x

26) Pararajalingam P, Coyle K.M, Arthur S.E, et al.

Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing

Blood, March 2020. https://doi.org/10.1182/blood.2019002385

27) Tordjman J, Majumder M, Amiri M, Hasan A, Hess D, Lala P.K.

Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells

BMC Cancer volume 19, Article number: 561 (2019). https://doi.org/10.1186/s12885-019-5771-5

28) Wang Y, Li G.

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

Frontiers of Medicine,13, pages 438–450 (2019). https://doi.org/10.1007/s11684-018-0674-4

29) Platko K, Haas-Neill S, Aziz T, Al-Nedawi K.

The role of circulating extracellular vesicles in breast cancer classification and molecular subtyping

The Breast Journal, September 2018. https://doi.org/10.1111/tbj.13309

30) Alaroui D.F, Johnston E.M, Farquharson M.J.

Comparison of two X-ray detection systems used to investigate properties ofnormal and malignant breast tissues

Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. February 2019, https://doi.org/10.1016/j.nima.2019.02.027

31) Hunter, S.; Nault, B.; Ugwuagbo, K.C.; Maiti, S.; Majumder, M.

Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer

Cancers 2019, 11(7), 938; https://doi.org/10.3390/cancers11070938


Canadian Tumour Repository Network

Biopreservation and Biobanking. December 2010, 8(4): 181-185. https://doi.org/10.1089/bio.2010.8405

33) Kelly R, Albert M, de Ladurantaye M, Moore M, Dokun O, Bartlett J.

RNA and DNA Integrity Remain Stable in Frozen Tissue After Long-Term Storage at Cryogenic Temperatures: A Report from the Ontario Tumour Bank

Biopreservation and Biobanking 2019. DOI:https://doi.org/10.1089/bio.2018.0095

34) Ding L, Bailey MH, Porta-Pardo E.

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

Cell 2018. 173, 305–320, DOI:https://doi.org/10.1016/j.cell.2018.03.033

35) Chen H, Li C, Peng X, Zhou Z, Weinstein JN, The Cancer Genome Atlas Research Network, Liang H.

A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

Cell 2018. 173, 386–399, DOI:https://doi.org/10.1016/j.cell.2018.03.027

36) Dufresne J, Bowden P, Thavarajah T, Florentinus‑Mefailoski A, et al.

The Plasma Peptides of Ovarian Cancer

Clin Proteom 2018. 15:41, DOI:https://doi.org/10.1186/s12014-018-9215-z

37) Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, et al.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

CANCER DISCOVERY 2018. CD-18-0804, DOI: https://doi.org/10.1158/2159-8290.cd-18-0804

38) Wang Y, Xu X, Maglic D, et al.

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer

Cell Reports 2018. 25, 1304–1317 , DOI:https://doi.org/10.1016/j.celrep.2018.10.001

39) Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, et al.

The chromatin accessibility landscape of primary human cancers

Science 26 Oct 2018: Vol. 362, Issue 6413, eaav1898 DOI: https://doi.org/10.1126/science.aav1898

40) Korkut A, Zaidi S, Kanchi RS, et al.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily

Cell Systems 2018. 7, 422–437, DOI:https://doi.org/10.1016/j.cels.2018.08.010

41) Kahles A, Lehmann K, Toussaint NC, et al.

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Cancer Cell 2018. 34, 211–224, DOI:https://doi.org/10.1016/j.ccell.2018.07.001

42) Shen H, Shih J, Hollern DP, et al.

Integrated Molecular Characterization of Testicular Germ Cell Tumors

Cell Reports 2018. 23, 3392–3406, DOI:https://doi.org/10.1016/j.celrep.2018.05.039

43) de Kock L, Fahiminiya S, Fiset PO, Astigarraga I, Nguyen VH, Albrecht S, Foulkes WD.

Infantile Pulmonary Teratoid Tumor

N Engl J Med. 2018 Jun 7;378(23):2238-2240. DOI: https://doi.org/10.1056/nejmc1803354

44) Thorsson V, Gibbs DL, Brown SD, et al.

The Immune Landscape of Cancer

Immunity 2018. 48, 812–830, DOI:https://doi.org/10.1016/j.immuni.2018.03.023

45) Wang Z, Yang B, Zhang M, et al.

lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer

Cancer Cell 2018. 33, 706–720, DOI:https://doi.org/10.1016/j.ccell.2018.03.006

46) Berger AC, Korkut A, Kanchi RS, et al.

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers

Cancer Cell 2018. 33, 690–705, DOI:https://doi.org/10.1016/j.ccell.2018.03.014

47) Liu Y, Sethi NS,Hinoue T, et al.

Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas

Cancer Cell 2018. 33, 721–735, DOI: https://doi.org/10.1016/j.ccell.2018.03.010

48) Taylor AM, Shih J, Ha G.

Genomic and Functional Approaches to Understanding Cancer Aneuploidy

Cancer Cell 2018. 33, 676–689, DOI:https://doi.org/10.1016/j.ccell.2018.03.007

49) Hoadley KA, Yau C, Hinoue T.

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

Cell 2018. 173, 291–304, DOI:https://doi.org/10.1016/j.cell.2018.03.022

50) Blum A, Wang P, Zenklusen JC.

SnapShot: TCGA-Analyzed Tumors

Cell 2018. 173(2):530. doi: https://doi.org/10.1016/j.cell.2018.03.059

51) Sanchez-Vega F, Mina M, Armenia J, et al.

Oncogenic Signaling Pathways in The Cancer Genome Atlas

Cell 2018. 173, 321–337, DOI:https://doi.org/10.1016/j.cell.2018.03.035

52) Liu J, Lichtenberg T, Hoadley KA, et al.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell 2018. 173, 400–416, doi:https://doi.org/10.1016/j.cell.2018.02.052

53) Bailey MH, Tokheim C, Porta-Pardo E et al.

Comprehensive Characterization of Cancer Driver Genes and Mutations

Cell 2018. 173, 371–385, doi: https://doi.org/10.1016/j.cell.2018.02.060

54) Malta TM, Sokolov A, Andrew J. Gentles, et al.

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

Cell 2018. 173, 338–354, doi: https://doi.org/10.1016/j.cell.2018.03.034

55) Huang K, Mashl RJ, Wu Y et al.

Pathogenic Germline Variants in 10,389 Adult Cancers

Cell 2018. 173, 355–370, doi:https://doi.org/10.1016/j.cell.2018.03.039

56) Ge Z, Leighton JS, Wang Y, et al.

Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

Cell Reports 2018. 23, 213–226, doi: https://doi.org/10.1016/j.celrep.2018.03.047

57) Campbell JD, Yau C, Bowlby R, et al.

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

Cell Reports 2018. 23, 194–212, doi: https://doi.org/10.1016/j.celrep.2018.03.063

58) Gao Q, Liang W, Foltz SM, et al.

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

Cell Reports 2018. 23, 227–238, doi: https://doi.org/10.1016/j.celrep.2018.03.050

59) Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, et al.

Genomic and Molecular Landscape of DNA Damage Repair Deficiency Across The Cancer Genome Atlas

Cell Reports 2018. 23, 239–254, doi: https://doi.org/10.1016/j.celrep.2018.03.076

60) Way GP, Sanchez-Vega F, La K, Armenia J, et al.

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

Cell Reports 2018. 23, 172–180, doi: https://doi.org/10.1016/j.celrep.2018.03.046

61) Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, et al.

Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

Cell Reports 2018. 23, 181–200, doi: https://doi.org/10.1016/j.celrep.2018.03.086

62) Chiu , S, Patel E, Chen T, Singh VP, et al.

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Cell Reports 2018. 23, 297–312, doi: https://doi.org/10.1016/j.celrep.2018.03.064

63) Seiler M, Peng A, Agrawal AA, Palacino J, et al.

Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

Cell Reports 2018. 23, 282–296, doi: https://doi.org/10.1016/j.celrep.2018.01.088

64) Jayasinghe RG, Cao S, Gao Q, Wendl MC, et al.

Systematic Analysis of Splice-Site-Creating Mutations in Cancer

Cell Reports 2018. 23, 270–281, doi: https://doi.org/10.1016/j.celrep.2018.03.052

65) Peng X, Chen Z, Farshidfar F, Xu X, et al.

Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

Cell Reports 2018. 23, 255–273, doi: https://doi.org/10.1016/j.celrep.2018.03.077

66) Ricketts C, De Cubas AA, Fan H, Smith CC, Lang M, et al.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

Cell Reports 2018. 23, 313–326, doi: https://doi.org/10.1016/j.celrep.2018.03.075

67) Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, et al.

Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines

Cell Systems 2018. 6, 271–281. doi: https://doi.org/10.1016/j.cels.2018.03.002

68) Schuab FX, Dhankani V, Berger AC, et al.

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

Cell Systems 2018. 6, 282–300. doi: https://doi.org/10.1016/j.cels.2018.03.003

69) Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, et al.

Characteristics and Outcome of the COEUR, Canadian Validation Cohort for Ovarian Cancer Biomarkers

BMC Cancer 2018. 18:347, doi: https://doi.org/10.1186/s12885-018-4242-8

70) Al-Hashimi A, Hoogenes J, Lebeau P, Shayegan B, Austin R.

Disrupting the Interaction Between Anti-GRP78 Autoantibodies and Cell Surface GRP78 With Low Molecular Weight Heparin as a Treatment for Prostate Cancer

European Urology Supplements 2018. Volume 17, Issue 2, Page e509. doi: https://doi.org/10.1016/S1569-9056(18)31200-4

71) Al-Hashimi A , Austin R, Shayegan B.

Cell Surface GRP78 Activation by Anti-GRP78 Autoantibodies in Relation to Prostate Tumour Growth via Tissue Factor Activation

Journal of Clinical Oncology 36, no. 6_suppl (February 20 2018) 31-31. DOI: https://doi.org/10.1200/JCO.2018.36.6_suppl.31

72) Radovich M, Pickering CR, Felau I, Ha G, Zhang H, et al.

The Integrated Genomic Landscape of Thymic Epithelial Tumors

Cancer Cell 2018. 33, 244–258 doi:https://doi.org/10.1016/j.ccell.2018.01.003

73) Quevedo R, Spreafico A, Bruce J, Danesh A, Giesler A, et al.

Genome Analysis and Data Sharing Informs Timing of Molecular Events in Pancreatic Neuroendocrine Tumour

bioRxiv 2018. doi:http://dx.doi.org/10.1101/232850

74) Majumder M, Dunn L, Liu L, Hasan A, Vincent K, Brackstone M, Hess D, Lala PK.

COX-2 Induces Oncogenic Micro RNA miR655 in Human Breast Cancer

Sci Rep. 2018 Jan 10;8(1):327. doi: 10.1038/s41598-017-18612-3.

75) Creed, J., Klotz, L., Harbottle, A. et al.

A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA ‘grey zone’

World J Urol (2018) 36: 341. https://doi.org/10.1007/s00345-017-2152-z

76) The Cancer Genome Atlas Group, Bartlett J, Sekhon H, Parfitt J.

Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas

Cell. 2017 November 02; 171(4): 950–965.e28. doi:https://doi.org/10.1016/j.cell.2017.10.014.

77) The Cancer Genome Atlas Group, Albert M, Alexopoulou V, Bartlett J, Paraffit J.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

Cell 2017. 171, 540–556 DOI: https://doi.org/10.1016/j.cell.2017.09.007

78) Skulimowski, et al.

53BP1 is a Novel Independent Predictive Biomarker in High-grade Serous Ovarian Cancer


79) Le Page C, Kobel M, Rahimi K, Bernardini M, Meunier L, Porlelance L, de Ladurantaye M.

Clinical Characteristics and Outcome of the COEUR Cohort, a Canadian Repository for Ovarian Cancer Biomarker Validation

Poster 2017

80) Communal, et al.

Validation of Biomarkers in Epithelial Ovarian Cancer


81) Al-Hashimi AA, Lebeau P, Majeed F, Polena E, Lhotak Š, Collins CAF, Pinthus JH, et al.

Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor

J. Biol. Chem.(2017) 292(51) 21180–21192 DOI: http://www.jbc.org/cgi/doi/10.1074/jbc.M117.799908

82) The Cancer Genome Atlas Group, Bartlett J, Albert M, Sekhon H.

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma

Cancer Cell 2017. 32:185–203, DOI: http://dx.doi.org/10.1016/j.ccell.2017.07.007

83) Parry-Jones A, Albert M.

The 2017 ISBER Annual Meeting & Exhibits: “Due North: Aligning Biobanking Practice with Evolving Evidence and Innovation”

Biopreservation and Biobanking 2017, 15(3), pp. 280–281 DOI: https://doi.org/10.1089/bio.2017.29024.apj

84) Crawford TE, Marcellus KA, Langill J, Ravel-Chapuis A, Michaud J, Cowan KN, Cote J, Jasmin BJ.

Novel Roles for Staufen1 in Embryonal and Alveolar Rhabdomyosarcoma Via c-myc-dependent and independent events

Scientific Reports 7:42342 (2017) DOI: 10.1038/srep42342

85) The Cancer Genome Atlas Group, Albert M, Bartlett J, Parfitt J, Arnaout A, Sekhon H, Gilbert S.

Integrated Genomic and Molecular Characterization of Cervical Cancer

Nature volume 543, pages 378–384, 23 January 2017, doi:10.1038/nature21386

86) Parry-Jones A, Albert M.

The 2017 ISBER Annual Meeting & Exhibits in Toronto “Due North: Aligning Biobanking Practice with Evolving Evidence and Innovation

Biopreservation and Biobanking 2016 Dec;14(6):563-564. Epub 2016 Nov 21 https://doi.org/10.1089/bio.2016.29013.apj

87) Au KK, Le Page C, Ren R, Meunier L, et al.

STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer

J Path: Clin Res October 2016; 2: 259–270 DOI: 10.1002/cjp2.55

88) Le Page C, Kobel M, Rahimi K, Bernardini M, Meunier L, Porlelance L, de Ladurantaye M.

COEUR: A pan Canadian platform for the development of biomarker-driven subtype specific management of ovarian cancer

Poster 2016

89) Al-Hashimi A, Shayegan B, Austin R.

Effect of anti-GRP78 autoantibodies on prostate cancer progression through tissue factor procoagulant activity

Journal of Clinical Oncology 34, no. 2_suppl (January 2016) 258-258. DOI: https://doi.org/10.1200/jco.2016.34.2_suppl.258

90) Le Page C, Kobel M, Rahimi K, Bernardini M, Meunier L, Porlelance L, de Ladurantaye M.

COEUR: A pan Canadian platform for the development of biomarker-driven subtype specific management of ovarian cancer


91) Henderson M, Simeon-Dubach D, Albert M.

Finding the Path to Biobank Sustainability Through Sound Business Planning

Biopreservation and Biobanking 2015 Dec;13(6):385-6 https://doi.org/10.1089/bio.2015.29039.mh

92) Barnes RO, Schacter B, Kodeeswaran S, CTRNet Management Committee, Watson PH.

Funding Sources for Canadian Biorepositories: The Role of User Fees and Strategies to Help Fill the Gap

Biopreservation and Biobanking. October 2014, 12(5): 300-305. https://doi.org/10.1089/bio.2014.0052

93) Nesset KA, Perri AM, Mueller CR.

Frequent Promoter Hypermethylation and Expression Reduction of the Glucocorticoid Receptor Gene in Breast Tumours

Epigenetics, 9:6, 851-859, DOI: https://doi.org/10.4161/epi.28484

94) Watson PH, Nussbeck SY, Carter C, O’Donoghue S,et al.

A Framework for Biobank Sustainability

Biopreservation and Biobanking. February 2014, 12(1): 60-68; https://doi.org/10.1089/bio.2013.0064

95) Matzke E A.M., O’Donoghue S, O. Barnes R, Daudt H, et al.

Certification for Biobanks: The Program Developed by the Canadian Tumour Repository Network (CTRNet)

Biopreserv Biobank. 2012 Oct;10(5):426-32. doi: https://doi.org/10.1089/bio.2012.0026

96) Kelly NJ, Varga JFA, Specker EJ, Romeo CM, Coomber BL, Uniacke J.

Hypoxia activates cadherin-22 synthesis via eIF4E2 to drive cancer cell migration, invasion and adhesion

Oncogene. 2017; doi:10.1038/onc.2017.372

97) Lachance G, Uniacke J, Audas TE, Holterman CE, Franovic A, Payette J, Lee S.

DNMT3a epigenetic program regulates the HIF-2α oxygen-sensing pathway and the cellular response to hypoxia

Proc Natl Acad Sci USA. 2014; 111(21): 7783–7788.

98) Köbel M, Rahimi K, Rambau PF, Naugler C, et al.

An Immunohistochemical Algorithm for Ovarian Carcinoma Typing

International Journal of Gynecological Pathology. 2016; 35:430–441. DOI: https://doi.org/10.1097/pgp.0000000000000274

99) The Cancer Genome Atlas Research Network.

Integrated genomic characterization of oesophageal carcinoma

Nature. 2017; doi:10.1038/nature20805.

100) Loiselle JJ, Roy JG, Sutherland LC.

RBM5 reduces small cell lung cancer growth, increases cisplatin sensitivity and regulates key transformation-associated pathways

Heliyon 2016 2(11): e00204, DOI: 10.1016/j.heliyon.2016.e00204

101) Majumder M, Xin X, Liu L, Tutunea-Fatan E, Rodriguez-Torres M, Vincent K, Postovit LM, Hess D, Lala PK.

COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis.

Stem Cells. 2016; 14. doi: 10.1002/stem.2426.

102) Ho N, Coomber B.

Hexokinase II expression is correlated with colorectal cancer prognosis.

Cancer Treatment and Research Communications. 2016; 6: 11-16. DOI: https://doi.org/10.1016/j.ctrc.2016.02.008

103) The Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, et al.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

N Engl J Med. 2016; 14:135-45. doi: 10.1056/NEJMoa1505917.

104) Hirte H, Hotte SJ, Kavsak PA.

Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancer.

Applied Mathematics, Medicine, Cell Biology, 2016; 2(1): DOI: 10.1016/j.heliyon.2015.e00059.

105) Majumder M, Landman E, Liu L, Hess D, et al.

COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.

Mol Cancer Res. 2015; 13:1022-33. doi: 10.1158/1541-7786.MCR-14-0543.

106) Koti M, Siu A, Clément I, et al.

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Br J Cancer. 2015; 113:1746. doi:10.1038/bjc.2015.459.

107) Albert M, Bartlett J, Johnston RN, et al.

Biobank bootstrapping: is biobank sustainability possible through cost recovery?

108) Fahmy N, Woo M, Alameldin M, et al.

Investigating Ochratoxin A and Biotin Levels in Patients with Renal Carcinoma.

Northeastern Section of the American Urological Association 64th Annual Meeting, Niagara Falls, Canada. September 2012. Moderated Poster

109) Fahmy N, Woo M, Alameldin M, et al.

Endogenous biotin expression in renal and testicular tumours and literature review.

Canadian Urological Association Journal. 2014; 8: 268- 272.doi:10.5489/cuaj.1810.

110) Matzke, Dee S, Bartlett J, et al.

A practical tool for modeling biospecimen user fees.

Biopreserv Biobank. 2014;12: 234-9. doi: 10.1089/bio.2014.0008.

111) The Cancer Genome Atlas Research Network.

Comprehensive molecular characterization of gastric adenocarcinoma.

Nature. 2014; 11: 202-9. doi: 10.1038/nature13480.

112) The Cancer Genome Atlas Research Network.

Comprehensive molecular profiling of lung adenocarcinoma.

Nature. 2014; 511:543-50. doi: 10.1038/nature13385.

113) The Cancer Genome Atlas Research Network.

Comprehensive molecular characterization of urothelial bladder carcinoma.

Nature. 2014; 507: 315-22. doi: 10.1038/nature12965.

114) Letellier E, Schmitz M, Baig K, et al.

Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer.

British Journal of Cancer. 2014; 111: 726-735.

115) Fahmy N, Woo M, Alameldin M, et al.

Ochratoxin A is not detectable in renal and testicular tumours.

Canadian Urological Association Journal. 2014; 8: 40-6.

116) Peltekova V, Lemire M, Qazi A, et al.

Identification of genes expressed by immune cells of the colon that are regulated by colorectal cancer-associated variants.

Int. J. Cancer: 2014; 134: 2330–2341.

117) Whiteside E, Seim I, O’Keeffe A, et al.

Identification of a long non-coding RNA gene, growth hormone secretagogue receptor opposite strand, which stimulates cell migration in non-small cell lung cancer cell lines.

International Journal of Oncology, 2013; 43: Issue 2.

118) Griffith M, Mwenifumbo J, Cheung P, et al.

Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer.

The Pharmacogenomics Journal. 2013; 13: 148–158.

119) Fontebasso A.

Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.

Acta Neuropathol. 2013; 125:659–669.

120) Nicholas J, Andersen BJ, Nickoloff KJ, et al.

Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.

Molecular Cancer Theraputics, 2013; 12: 1701-1714.

121) Dulak A, Stojanov P, Peng S, et al.

Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.

Nature Genetics 2013; 45: 478-486.

122) Novak A, Binnington B, Ngan B, et al.

Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodectection in human cancer biopsies.

Glycobiology. 2013; 23.1230-9.

123) Koti M, Gooding R, Nuin P, et al.

Identification of the IGF1/PI3K/NF κB/ERK gene signaling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

BMC Cancer. 2013; 13: 549.

124) Farquharson M, Al-Ebraheem A, Cornacchi G, et al.

The use of X-ray interaction data to differentiate malignant from normal breast tissue at surgical margins and biopsy analysis.

X-Ray Spectrom. 2013; 42, 349–358.

125) The Cancer Genome Atlas Research Network.

Integrated genomic characterization of endometrial carcinoma.

Nature. 2013: 497, 67-73. doi: 10.1038/nature12113.

126) Barnes R, Albert M, Damaraju S, et al.

Generating a comprehensive set of standard operating procedures for a biorepository network-The CTRNet experience.

Biopreserv Biobank. 2013; 11:387-96. doi: 10.1089/bio.2013.0061.

127) Hembrough T, Thyparambil S, Liao W.

Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumour Tissue.

The Journal of Molecular Diagnostics. 2013; 15: 454-465.

128) Thériault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL.

Kinesin family member 14: An independent prognostic marker and potential therapeutic target for ovarian cancer.

Int. J. Cancer. 2012; 130: 1844–1854. doi:10.1002/ijc.26189.

129) Haslehurst AM, Koti M, Dharsee M, et al.

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

BMC Cancer. 2012;12:91. doi:10.1186/1471-2407-12-91.

130) Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, et al.

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Nature. 2012;482:226–231.

131) Pinto DM, Chisholm K, O’Connor-McCourt M, Wang E, Leslie A, Kostyleva R, Cohen A.

Intra-protein variability revealed by absolute quantification of plasma proteins using dimethyl labelling.

Paper presented at: 4th Annual Symposium of the Canadian National Proteomics Network; 2012 Apr 23-25; Toronto, ON.

132) Fahmy N, Woo M, MacDonald K, Goneau L, Cadieux P, Pautler S.

Investigating Ochratoxin A and Biotin Levels in Patients with Renal Carcinoma.

Paper presented at: 64th Annual Meeting of the Northeastern Section of the American Urological Association; 2012 Sep 13-15; Niagara Falls.

133) The Cancer Genome Atlas Research Network.

Comprehensive genomic characterization of squamous cell lung cancers.

Nature.2012; 489(7417), 519–525. http://doi.org/10.1038/nature11404

134) Quail DF, Walsh LA, Zhang G, et al.

Embryonic protein nodal promotes breast cancer vascularization.

Cancer Research. 72; 3851–63.

135) Laguë M-N, Romieu-Mourez R, Bonneil É, Boyer A, Pouletty N, Mes-Masson A-M, et al.

Proteomic Profiling of a Mouse Model for Ovarian Granulosa Cell Tumor Identifies VCP as a Highly Sensitive Serum Tumor Marker in Several Human Cancers.

PLoS ONE. 2012; 7(8): e42470. doi:10.1371/journal.pone.0042470.

136) Rico C, Lague MN, Lefevre P, Tsoi M, Dodelet-Devillers A, Kumar V, et al.

Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.

Carcinogenesis. 2012;33(11):2283–92. doi: 10.1093/carcin/bgs263.

137) Chikova A, Bernard HU, Shchepotin IB, Grando SA.

New associations of the genetic polymorphisms in nicotinic receptor genes with the risk of lung cancer.

Life Sciences. 2012; 91(21-22), 1103–1108. http://doi.org/10.1016/j.lfs.2011.12.023.

138) Mersov A, Mersov G, Al-Ebraheem A, Cornacchi S, Gohla G, Lovrics P, Farquharson MJ.

The differentiation of malignant and benign human breast tissue at surgical margins and biopsy using x-ray interaction data and Bayesian classification.

Radiation of Physics and Chemistry.2012; 95: 210-2013. http://dx.doi.org/10.1016/j.radphyschem.2012.12.014.

139) Girgis AH, Iakovlev VV, Beheshti B, et al.

Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma.

Cancer Research. 2012;72(20):5273–5284. doi: 10.1158/0008-5472.CAN-12-0656.

140) Li Q, Tainsky MA.

Epigenetic Silencing of IRF7 and/or IRF5 in Lung Cancer Cells Leads to Increased Sensitivity to Oncolytic Viruses.

PLoS ONE. 2011; 6(12), e28683. http://doi.org/10.1371/journal.pone.0028683.

141) Ward A, Morettin A, Shum D, Hudson JW.

Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice.

BMC cancer. 2011; 71. doi:101186/1471-2407-11-71.

142) Huang Y, Sohn KY, Phan K, Dhesy-Thind S, Hill S, Hirte H, Hotte S, Worster A, Kavsak P.

NT-proBNP measurement using a multiplex platform in cancer and chest pain populations.

Clinical Biochemistry. 2011; 44: 1172.

143) Cin H, Meyer C, Herr R, et al.

Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.

Acta Neuropathol. 2011; 121: 763. doi:10.1007/s00401-011-0817-z.

144) Lambrot R, Kimmins S.

Histone methylation is a critical regulator of the abnormal expression of POU5F1 and RASSF1A in testis cancer cell lines.

International Journal of Andrology. 2011; 34: 110–123. doi:10.1111/j.1365-2605.2010.01063.x

145) Hill J, Tremblay TL, Pent A, Li J, Robotham A, Lenferink AE, Wang E, O’Connor-McCourt M, Kelly JF.

Identification of vascular breast tumour markers by laser capture microdissection and label-free LC-MS.

J Proteome Res. 2011; 10(5): 2479-2493.

146) White NMA, et al.

miRNA Profiling in Metastatic Renal Cell Carcinoma Reveals a Tumour-Suppressor Effect for miR-215.

British Journal of Cancer. 2011; 105(11): 1741–1749.

147) Huang Y, Dhesy-Thind S, Hirte H, Hotte S, Kavsak P.

Establishing a reference interval for the high sensitive Troponin T assay in treatment-naïve cancer patients.

Accepted abstract in: AACC; 2011.

148) Jha KN, Wong L, Zerfas PM, et al.

Identification of a Novel HSP70-binding Cochaperone Critical to HSP90-mediated Activation of Small Serine/Threonine Kinase.

The Journal of Biological Chemistry. 2010; 285(45):35180-35187. doi:10.1074/jbc.M110.134767.

149) Weerawardane S.

Analyzing The Biological Role Of The Transcription Factor Kaiso In Breast Tumourigenesis.

Graduate Studies. McMaster University, 2010. Print.

150) Misquitta-Ali CM, Cheng E, O’Hanlon D, et al.

Global Profiling and Molecular Characterization of Alternative Splicing Events Misregulated in Lung Cancer.

Molecular and Cellular Biology. 2011; 31(1):138-150. doi:10.1128/MCB.00709-10.

151) Henley SA, Francis SM, Demone J, Ainsworth P, Dick FA.

A cancer derived mutation in the Retinoblastoma gene with a distinct defect for LXCXE dependent interactions.

Cancer Cell International. 2010; 10:8. doi:10.1186/1475-2867-10-8.

152) Al-Halabi H, Nantel A, Klekner A, et al.

Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma.

Acta Neuropathol. 2010; 121: 229. doi:10.1007/s00401-010-0780-0.

153) Donaldson NS, Nordgaard CL, Pierre CC, Kelly KF, Robinson SC, et al.

Kaiso regulates Znf131-mediated transcriptional activation.

Exp Cell Res. 2010; 316: 1692–1705.

154) Lu X, Zhang K, Van Sant C, et al.

An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models.

BMC Med Genomics. 2010; 3: 23.

155) Henderson MPA, Hirte H, Hotte SJ, Kavsak PA.

Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancer.

Heliyon. 2010; 2(1):e00059. doi:10.1016/j.heliyon.2015.e00059.

156) Englert D, Wilson D, Laken S.

Amplification of mRNA from Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues without 3′ Bias and Multiplex Expression Analysis on Flow-Through Microarrays.

Cancer Res. 2009; 69: 3052; DOI: 10.1158/0008-5472.SABCS-09-3052.

157) Kavsak PA, Lee A, Hirte H, Young E, Gauldie J.

Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies.

Clin Biochem. 2008; 41:607–610.

158) Kavsak PA, Lee A, Hirte H, Young E, Gauldie J.

Pilot study assessing the utility of an adhesion array and high-sensitivity cytokine array as surrogate biomarkers in ovarian cancer.

Clin Biochem. 2008; 41:1271.